Response of non-Hodgkin lymphoma to radiation therapy

Early and long-term assessment with H-1 MR spectroscopic imaging

Alberto Bizzi, Benjamin Movsas, Gioacchino Tedeschi, Carrie L. Phillips, Paul Okunieff, Jeffry R. Alger, Giovanni Di Chiro

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy. MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained. RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirtythree months after treatment, multiple-section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined. CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalRadiology
Volume194
Issue number1
Publication statusPublished - Jan 1995

Fingerprint

Non-Hodgkin's Lymphoma
Magnetic Resonance Spectroscopy
Radiotherapy
Magnetic Resonance Imaging
Choline
Lipids
Creatine
Therapeutics
Protons
Hydrogen
Lymphoma
Recurrence
Brain
Neoplasms

Keywords

  • Brain neoplasms, emission CT, 132.12145
  • Brain neoplasms, secondary, 132.343
  • Hodgkin disease, therapeutic radiology, 132.343
  • Magnetic resonance (MR), spectroscopy, 132.12145

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Bizzi, A., Movsas, B., Tedeschi, G., Phillips, C. L., Okunieff, P., Alger, J. R., & Di Chiro, G. (1995). Response of non-Hodgkin lymphoma to radiation therapy: Early and long-term assessment with H-1 MR spectroscopic imaging. Radiology, 194(1), 271-276.

Response of non-Hodgkin lymphoma to radiation therapy : Early and long-term assessment with H-1 MR spectroscopic imaging. / Bizzi, Alberto; Movsas, Benjamin; Tedeschi, Gioacchino; Phillips, Carrie L.; Okunieff, Paul; Alger, Jeffry R.; Di Chiro, Giovanni.

In: Radiology, Vol. 194, No. 1, 01.1995, p. 271-276.

Research output: Contribution to journalArticle

Bizzi, A, Movsas, B, Tedeschi, G, Phillips, CL, Okunieff, P, Alger, JR & Di Chiro, G 1995, 'Response of non-Hodgkin lymphoma to radiation therapy: Early and long-term assessment with H-1 MR spectroscopic imaging', Radiology, vol. 194, no. 1, pp. 271-276.
Bizzi A, Movsas B, Tedeschi G, Phillips CL, Okunieff P, Alger JR et al. Response of non-Hodgkin lymphoma to radiation therapy: Early and long-term assessment with H-1 MR spectroscopic imaging. Radiology. 1995 Jan;194(1):271-276.
Bizzi, Alberto ; Movsas, Benjamin ; Tedeschi, Gioacchino ; Phillips, Carrie L. ; Okunieff, Paul ; Alger, Jeffry R. ; Di Chiro, Giovanni. / Response of non-Hodgkin lymphoma to radiation therapy : Early and long-term assessment with H-1 MR spectroscopic imaging. In: Radiology. 1995 ; Vol. 194, No. 1. pp. 271-276.
@article{1d940cfa3ff54a9f959558481526acfe,
title = "Response of non-Hodgkin lymphoma to radiation therapy: Early and long-term assessment with H-1 MR spectroscopic imaging",
abstract = "PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy. MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained. RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirtythree months after treatment, multiple-section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined. CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.",
keywords = "Brain neoplasms, emission CT, 132.12145, Brain neoplasms, secondary, 132.343, Hodgkin disease, therapeutic radiology, 132.343, Magnetic resonance (MR), spectroscopy, 132.12145",
author = "Alberto Bizzi and Benjamin Movsas and Gioacchino Tedeschi and Phillips, {Carrie L.} and Paul Okunieff and Alger, {Jeffry R.} and {Di Chiro}, Giovanni",
year = "1995",
month = "1",
language = "English",
volume = "194",
pages = "271--276",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Response of non-Hodgkin lymphoma to radiation therapy

T2 - Early and long-term assessment with H-1 MR spectroscopic imaging

AU - Bizzi, Alberto

AU - Movsas, Benjamin

AU - Tedeschi, Gioacchino

AU - Phillips, Carrie L.

AU - Okunieff, Paul

AU - Alger, Jeffry R.

AU - Di Chiro, Giovanni

PY - 1995/1

Y1 - 1995/1

N2 - PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy. MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained. RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirtythree months after treatment, multiple-section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined. CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.

AB - PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy. MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained. RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirtythree months after treatment, multiple-section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined. CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.

KW - Brain neoplasms, emission CT, 132.12145

KW - Brain neoplasms, secondary, 132.343

KW - Hodgkin disease, therapeutic radiology, 132.343

KW - Magnetic resonance (MR), spectroscopy, 132.12145

UR - http://www.scopus.com/inward/record.url?scp=0028950022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028950022&partnerID=8YFLogxK

M3 - Article

VL - 194

SP - 271

EP - 276

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -